SYK
Stryker Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -3.5% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 7 | 0 | 2.75M | $746.85M | n/a | n/a |
| Q2 2026 | 172 | +2 | 222.54M | $70.41B | +7 | −4 |
| Q1 2026 | 172 | -2 | 215.42M | $70.87B | +1 | −4 |
| Q4 2025 | 173 | -1 | 229.53M | $80.67B | +1 | −1 |
| Q3 2025 | 25 | +3 | 142.80M | $52.79B | +4 | −2 |
| Q2 2025 | 20 | 0 | 117.11M | $46.33B | +1 | −1 |
| Q1 2025 | 17 | -2 | 51.08M | $19.01B | n/a | −2 |
| Q4 2024 | 19 | 0 | 52.07M | $18.75B | +1 | −1 |
| Q3 2024 | 18 | +2 | 39.19M | $14.15B | +2 | n/a |
| Q2 2024 | 16 | n/a | 41.27M | $14.03B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 14.78M | n/a | $5.33B | 0.2% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 11.11M | +0.5% | $4.00B | 0.5% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | Wellington Management ✦ | 8.38M | -17.0% | $3.02B | 0.6% | ▼ Trim | 3 | SEC ↗ ×7 |
| 4 | Geode Capital Management ✦ (passive) | 7.07M | +2.4% | $2.54B | 0.2% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 4.75M | -0.6% | $1.71B | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 6 | Fisher Asset Management ✦ | 4.08M | -3.8% | $1.47B | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 607.20K | -8.9% | $218.62M | 0.3% | ▼ Trim | 3 | SEC ↗ ×2 |
| 8 | PRIMECAP Management ✦ | 436.10K | -2.5% | $157.02M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 9 | Point72 Asset Management ✦ | 214.24K | New | $77.14M | 0.2% | New | 1 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 144.39K | -18.6% | $51.99M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 11 | Two Sigma Investments ✦ | 135.67K | -29.5% | $48.85M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 101.04K | -19.0% | $36.38M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 13 | Arrowstreet Capital ✦ | 96.09K | -67.5% | $34.60M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Millennium Management ✦ | 73.64K | +136.0% | $26.52M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | Bridgewater Associates ✦ | 39.87K | -32.7% | $14.35M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 16 | GAMCO Investors ✦ | 21.57K | +17.1% | $7.77M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 18.14K | -52.1% | $6.53M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 18 | Gotham Asset Management ✦ | 4.25K | +139.8% | $1.53M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 19 | Marshall Wace ✦ | 2.90K | -80.2% | $1.04M | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $77.14M | 0.2% |
Exited
| Renaissance Technologies | $16.40M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 2,274 holders, 283.44M shares, $87.41B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 18 sh @ 225.19 · $4,054
Director · 3 sh @ 185.65 · $557
Director · 36 sh @ 193.21 · $6,956
Director · 11 sh @ 221.03 · $2,431
Director · 63 sh @ 202.21 · $12,739
Open-market sales (S)
Officer · 441 sh · $144,915
Director · 11.26K sh · $3.81M
Director · 40 sh · $13,272
Director · 440 sh · $146,598
Director · 200 sh · $66,786
Director · 80 sh · $26,804
Director · 320 sh · $107,774
Director · 2.31K sh · $780,062
Director · 10.81K sh · $3.67M
Director · 16.61K sh · $5.66M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology